Options traders are growing cautious on CCI even as short sellers retreat. Three distinct signals are now pulling in opposite directions — and the tension is worth watching.
Barclays analyst Brendan Lynch upgraded CCI to Overweight on August 20. But the upgrade came with a target cut — from $92 to $84. That implies roughly 10% upside from Tuesday's $76.29 close, but also signals Lynch sees less value than he did before. The consensus remains a Hold. The mean analyst price target sits at $95.07 — well above where the stock trades. Five firms have lowered their targets since late July, including Citigroup (to $98 from $106), JP Morgan (to $85 from $95), and Truist Securities (to $87 from $95). The direction is consistent: street expectations are coming down.
The put-call ratio hit 0.59 on August 25. That's nearly three standard deviations above the 20-day mean of 0.46. It's also within reach of the 52-week high of 0.65. The move is recent and sharp — the PCR was running at a steady 0.45 for most of August before jumping to 0.57 on August 24 and 0.59 the following day. Options traders are buying protection at a pace not seen in months.
Short interest fell 21% in a single day on August 25, dropping to 2.17% of free float. That's the lowest level in over a month. Over the past week, shorts are down 23%. Over the past month, down 27%. At 2.17% of float, the absolute level is low — not a squeeze story. But the speed of the exit is notable. The borrow market confirms there's no squeeze pressure: availability stands at over 5,600%, meaning shares to borrow are extremely plentiful and cost to borrow is just 0.39%.
The picture that emerges is mixed. Shorts are leaving quickly — that's covering, not conviction. Options traders are simultaneously hedging against downside. Analysts are upgrading the rating while slashing targets. None of these signals point cleanly in one direction. The factor scores add nuance: the analyst recommendation differential ranks in the 93rd percentile, suggesting CCI is better-positioned versus peers than its stock price implies. EPS momentum over 30 days ranks at the 76th percentile. Next earnings are scheduled for October 21.
See the live data behind this article on ORTEX.
Open CCI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
